Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to Aflibercept for Bevacizumab-Resistant DME
NCT03974425Completed
- Sponsor
- Alexandria University
- Start
- Apr 2016
- Primary completion
- Apr 2017
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
01
Overview
Open-label, single-arm trial of aflibercept in diabetic macular edema (DME), sponsored by Alexandria University. Primary endpoint: Central Macular Thickness at 12 months. Started Apr 2016; status: completed.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT03974425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03974425.